Tempus AI stock surges as Next platform expands to six new cancer types ahead of ASCO

Why Is Tempus AI Stock Surging On Thursday? - Tempus AI (NASDAQ:TEM)

Tempus AI Inc (NASDAQ:TEM) stock is trading higher on Thursday morning following a key product expansion announcement. The company revealed a significant expansion of new indications for its AI-enabled Next platform. The update comes just ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The platform establishes a new category of real-time clinical intelligence to advance precision medicine, moving away from legacy retrospective analyses. Expanding Cancer Scenario Insights The expanded platform will now surface patient insights across six new clinical scenarios. These cover breast, colorectal, ovarian, prostate and urothelial cancers. Additionally, Next introduced advanced intelligence capabilities. These features allow precision medicine teams to map patient experiences and develop targeted care gap programs. To showcase the real-world impact, Tempus will present a study at ASCO 2026 demonstrating improvements in biomarker testing rates for early-stage non-small cell lung cancer (eNSCLC). Eliminating Data Fragmentation The platform analyzes unstructured EHR data to identify patients missing guideline-directed testing. "The true challenge in precision oncology is the data fragmentation that hides critical care gaps across the patient journey," stated Ryan Fukushima, CEO of Data and Apps at Tempus, in the announcement. "By expanding Next, we are providing our health systems partners with a 360-degree view to not only identify these gaps but to quantify the truly addressable opportunities for intervention." Critical Levels To Watch for TEM Stock TEM is back above its shorter-term trend gauges, trading 4.6% above the 20-day SMA and 4.1% above the 50-day SMA, which helps explain why dip-buyers are showing up on Thursday. The bigger picture is still heavy, though, with shares 5.5% below the 100-day SMA and 22.9% below the 200-day SMA. The moving-average structure also argues this is still a repair phase: the 20-day SMA remains below the 50-day SMA, and the death cross (50-day below the 200-day) that triggered in January is still in place. RSI is the cleaner momentum read right now, sitting at 45.66. From a level-to-level standpoint, the stock is still well off its 52-week high of $104.32 and closer to the lower end of the range after the March swing low and 52-week low zone. * Key Resistance: $56.50 * Key Support: $42.50 TEM Price Action: Tempus AI shares were up 8.36% at $51.11 at the time of publication on Thursday, according to Benzinga Pro data. This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. Market News and Data brought to you by Benzinga APIs To add Benzinga News as your preferred source on Google, click here.

Tempus AI presents multimodal foundation model results at ASCO By Investing.com

CHICAGO - Tempus AI, Inc. (NASDAQ:TEM) announced results from its multimodal foundation models at the 2026 American Society of Clinical Oncology Annual Meeting today, according to a press release statement. The company's shares jumped 11% over the past week, trading at $51.29 and valuing the AI-driven precision medicine firm at $9.2 billion. The company's transformer-based model was trained on 2.5 million longitudinal records, including more than 250 million pages of clinical notes, 450,000 digitized medical images, and 500,000 genomic and transcriptomic sequences. The model draws from Tempus's database of more than 45 million de-identified patient journeys, with 1.5 million containing sequenced data. In a zero-shot analysis of EGFR-mutant non-small cell lung cancer patients treated with osimertinib, the model demonstrated a C-index of 0.802 for overall survival with a p-value below 0.001. The model showed a hazard ratio of 4.536 between high- and low-risk patient subgroups. The model produced prognostic value independent of molecular and clinical subgroups, stratifying overall survival of TP53-positive patients with a hazard ratio of 5.96 and progression-free survival in patients without CNS metastasis with a hazard ratio of 1.94.While Tempus continues to invest heavily in AI development, the company remains unprofitable with revenue of $1.36 billion over the last twelve months, though sales surged 70% year-over-year. According to InvestingPro analysis, the stock appears overvalued at current levels. Investors can access detailed valuation metrics and a comprehensive Pro Research Report on TEM, one of 1,400+ US equities covered with expert analysis. Tempus reported the model assessed cohorts mirroring clinical trials KEYNOTE-189, FLAURA-2, and DESTINY in non-small cell lung cancer, outperforming standard Cox-PH modeling approaches in zero-shot settings. "Foundation models, combined with agentic workflows, will help unlock the full potential of precision medicine," said Eric Lefkofsky, founder and CEO of Tempus. The company stated its database contains more than 500 petabytes of data, including over 400,000 cancer records with genomic, transcriptomic, imaging, and clinical data. The model is designed to address prediction objectives anchored in overall survival and progression-free survival without requiring additional data or model fine-tuning. In other recent news, Tempus AI, Inc. has received FDA approval for a tumor-only indication for its xT CDx next-generation sequencing platform. This approval allows Tempus to be the first laboratory to hold FDA companion diagnostic approval for both tumor-only and tumor-normal comprehensive genomic profiling. The test can now operate as a tumor-only assay when a matched normal specimen is unavailable. Additionally, Tempus announced an expansion of its Next platform to include six new cancer types, covering breast, colorectal, ovarian, prostate, and urothelial cancers. The company presented a study at the American Society of Clinical Oncology Annual Meeting, showcasing its AI-enabled clinical decision support system's implementation across 662 early-stage non-small cell lung cancer patients. Furthermore, Tempus upgraded its Tempus Hub platform by integrating generative AI capabilities to assist healthcare providers in treating cancer patients. This upgrade connects AI capabilities with real-time patient data, offering access to test orders, results, treatment options, clinical trial information, and biomarker tracking. These developments highlight Tempus AI's ongoing efforts to enhance its cancer treatment platforms. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.